• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Marrone Bio Innovations Inc.

    2/8/22 5:09:03 PM ET
    $MBII
    Major Chemicals
    Basic Industries
    Get the next $MBII alert in real time by email
    SC 13G 1 marrone_13g.htm SC 13G
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    Marrone Bio Innovations, Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    57165B106

     

    (CUSIP Number)

     

    December 31, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

     

    Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     
     
    CUSIP No. 57165B106 13G Page 2 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Ardsley Advisory Partners LP

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    Delaware, United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 18,335,767
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 18,335,767
    9. aggregate amount beneficially owned by each reporting person 18,335,767
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 10.35%
    12. type of reporting person (See Instructions) PN, IA

     
     
    CUSIP No. 57165B106 13G Page 3 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Ardsley Advisory Partners GP LLC

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    Delaware, United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 18,335,767
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 18,335,767
    9. aggregate amount beneficially owned by each reporting person 18,335,767
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 10.35%
    12. type of reporting person (See Instructions) OO

     
     

    CUSIP No. 57165B106 13G Page 4 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Ardsley Partners I GP LLC

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    Delaware, United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 18,335,767
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 18,335,767
    9. aggregate amount beneficially owned by each reporting person 18,335,767
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 10.35%
    12. type of reporting person (See Instructions) OO

     
     
    CUSIP No. 57165B106 13G Page 5 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Philip J. Hempleman

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 18,335,767
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 18,335,767
    9. aggregate amount beneficially owned by each reporting person 18,335,767
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 10.35%
    12. type of reporting person (See Instructions) IN

     
     

    CUSIP No. 57165B106 13G Page 6 of 11 Pages

                 
    1.

    names of reporting persons

    i.r.s. identification no. of above persons (entities only)

     

    Ardsley Partners Renewable Energy Fund, L.P.

     

    2. check the appropriate box if a group*

    (a) x

    (b) o

    3.

    sec use only

     

     

    4.

    citizenship or place of organization

    Delaware, United States of America

     

    number of
    shares
    5. sole voting power 0
    beneficially
    owned by
    6. shared voting power 18,309,267
    each
    reporting
    7. sole dispositive power 0
    person with: 8. shared dispositive power 18,309,267
    9. aggregate amount beneficially owned by each reporting person 18,309,267
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o 
    11. percent of class represented by amount in row (9) 10.34%
    12. type of reporting person (See Instructions) PN

     
     
    CUSIP No. 57165B106 13G Page 7 of 11 Pages

     

    Item 1.
      (a)  Name of Issuer: Marrone Bio Innovations, Inc.
      (b)  Address of Issuer’s Principal Executive Offices:

    1540 Drew Avenue

    Davis, California 95618

     
    Item 2.
      (a)  Name of Person Filing: This Schedule 13G (the “Schedule”) is being filed with respect to shares of Common Stock (as defined below) of Marrone Bio Innovations, Inc. (the “Issuer”) which are beneficially owned by Ardsley Advisory Partners LP (the “Advisor”), Ardsley Advisory Partners GP LLC (the “Advisor General Partner”), Ardsley Partners I GP LLC (the “General Partner”), Phillip J. Hempleman (“Hempleman”), and Ardsley Partners Renewable Energy Fund, L.P. (the “Renewable Energy Fund”, and together with the Advisor, the Advisor General Partner, the General Partner, and Hempleman, collectively, the “Reporting Persons”). See Item 4 below.  
      (b)  Address of Principal Business Office or, if none, Residence:

    262 Harbor Drive

    Stamford, CT 06902

      (c)  Citizenship: Each of the Advisor and the Renewable Energy Fund is a Delaware limited partnership. Each of the Advisor General Partner and the General Partner is a Delaware limited liability company. Hempleman is a United States Citizen.
      (d)  Title of Class of Securities: Common Stock
      (e)  CUSIP Number: 57165B106
               

    Item 3.              If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     
     

    CUSIP No. 57165B106 13G Page 8 of 11 Pages

     

    Item 4.              Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The Information required by Items 4(a) - (c) is set forth in Rows 5-11 of the cover page for each Reporting Person hereto and is incorporated by reference for each Reporting Person. The percentage ownership of the Reporting Persons is based on the 177,152,701 outstanding shares of Common Stock of the Issuer, as disclosed on the Issuer’s 10-Q filed with the SEC on November 10, 2021.

     

    Item 5.              Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o.

     

    Item 6.              Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.              Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.              Identification and Classification of Members of the Group.

     

    See Exhibit 2.

     

    Item 9.              Notice of Dissolution of Group.

     

    Not applicable.

     
     
    CUSIP No. 57165B106 13G Page 9 of 11 Pages

     

    Item 10. Certification
    (a)

     

    The following certification shall be included if the statement is filed pursuant to §240.13d-1(b) with respect to Ardsley Advisory Partners LP:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x

       
    (b)

    The following certification shall be included if the statement is filed pursuant to §240.13d-1(b) with respect to Ardsley Advisory Partners GP LLC:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x

       
    (c)

    The following certification shall be included if the statement is filed pursuant to §240.13d-1(b) with respect to Ardsley Partners I GP LLC:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x

       
    (d)

    The following certification shall be included if the statement is filed pursuant to §240.13d-1(c) with respect to Philip J Hempleman :

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x

       
    (e)

    The following certification shall be included if the statement is filed pursuant to §240.13d-1(c) with respect to Ardsley Partners Renewable Energy Fund, L.P.:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x

     
     

    CUSIP No. 57165B106 13G Page 10 of 11 Pages

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 8, 2022  
      Date  
         
      ARDSLEY ADVISORY PARTNERS LP  
     

    By: Ardsley Advisory Partners GP LLC, its general partner

     
         
      /s/ Steve Napoli  
      Signature  
         
      Steve Napoli/ Member  
      Name/Title  
         
      February 8, 2022  
      Date  
         
      ARDSLEY ADVISORY PARTNERS GP LLC  
         
      /s/ Steve Napoli  
      Signature  
         
     

    Steve Napoli/ Member

     
     

    Name/Title

     
         
      February 8, 2022  
      Date  
         
      ARDSLEY PARTNERS I GP LLC  
         
      /s/ Steve Napoli  
      Signature  
         
      Steve Napoli/ Member  
      Name/Title  

     
     
    CUSIP No. 57165B106 13G Page 11 of 11 Pages

     

      February 8, 2022  
      Date  
         
      PHILIP J. HEMPLEMAN  
         
      /s/ Steve Napoli*  
      Signature  
         
      Steve Napoli/Attorney-in Fact for Philip J. Hempleman  
     

    Name/Title

     
         
      February 8, 2022  
      Date  
         
      ARDSLEY PARTNERS RENEWABLE ENERGY FUND, L.P.  
     

    By: Ardsley Partners I GP LLC, its general partner

     
         
      /s/ Steve Napoli  
      Signature  
         
     

    Steve Napoli/ Member

     
     

    Name/Title

     

     

    * Executed by Steve Napoli as Attorney-in-Fact for Philip J. Hempleman. The Power of Attorney for Mr. Hempleman is attached as Exhibit 2 to the Statement on Schedule 13G with respect to the Common Stock of Vaxgen, Inc., filed on February 15, 2006, and is incorporated herein by reference.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
    Get the next $MBII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBII

    DatePrice TargetRatingAnalyst
    9/22/2021$2.00Buy
    Roth Capital
    8/19/2021$3.50 → $2.50Buy
    Aegis Capital
    More analyst ratings

    $MBII
    Financials

    Live finance-specific insights

    See more
    • Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results

      RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the low- to mid-teens on a percentage basis.Gross profit of $6.2 million and gross margins of 55.9% reflected changes in product mix, higher raw material

      5/11/22 4:01:00 PM ET
      $BIOX
      $MBII
      Agricultural Chemicals
      Industrials
      Major Chemicals
      Basic Industries
    • Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time

      RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations' first quarter financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q1 2022 Conference Call and Webcast Date: Wednesday, May 11, 2022Time: 4:30 p.m

      4/27/22 8:00:00 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results

      RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was $16.6 million and Adjusted EBITDA1 loss was $8.7 million, improvements of 17.9% and 21.2%, respectively.As announced March 16, 2022, Marrone Bio and Bioceres Crop So

      3/28/22 4:01:00 PM ET
      $BIOX
      $MBII
      Agricultural Chemicals
      Industrials
      Major Chemicals
      Basic Industries

    $MBII
    Leadership Updates

    Live Leadership Updates

    See more
    • 180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors

      MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors (“Board”) effective upon the earlier of (a) the business day following the filing of the 2020 Form 10-K Annual Report; and (b) June 28, 2021. The Board also changed the effective dates of the appointments of Russell T. Ray, MBA and Teresa DeLuca MD, MBA as members of the Board, as previously announced

      6/10/21 9:12:32 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • Marrone Bio Appoints Sue Cheung New Chief Financial Officer

      DAVIS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today that Suping (Sue) Cheung has been appointed chief financial officer, effective Feb. 18, 2021. She succeeds James Boyd, who previously announced his intention to retire. Cheung, a certified public accountant, brings to Marrone Bio 28 years of experience in international strategic and financial operations, including financial reporting, forecasting and budgeting; mergers and acquisitions; equity and debt financing; internal controls; and inves

      1/28/21 9:00:00 AM ET
      $QUIK
      $MBII
      Semiconductors
      Technology
      Major Chemicals
      Basic Industries

    $MBII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Vasavada Amit was granted 129,184 shares and returned 285,892 shares to the company, closing all direct ownership in the company

      4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)

      7/15/22 11:15:05 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form 4: Johnson Timothy B was granted 102,167 shares and returned 212,374 shares to the company, closing all direct ownership in the company

      4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)

      7/15/22 11:13:32 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form 4 filed by Ospraie Ag Science Llc

      4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)

      7/15/22 9:09:02 AM ET
      $MBII
      Major Chemicals
      Basic Industries

    $MBII
    SEC Filings

    See more
    • SEC Form 15-12G filed by Marrone Bio Innovations Inc.

      15-12G - Pro Farm Group, Inc. (0001441693) (Filer)

      9/2/22 6:17:10 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form EFFECT filed by Marrone Bio Innovations Inc.

      EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)

      8/30/22 12:15:26 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form EFFECT filed by Marrone Bio Innovations Inc.

      EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)

      8/30/22 12:15:28 AM ET
      $MBII
      Major Chemicals
      Basic Industries

    $MBII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ROTH MKM's Agribusiness Investment Banking Group Sees Success with the Closing of Three M&A Sellside Transactions

      ROTH MKM ("Roth"), www.roth.com, a relationship-driven investment bank focused on serving growth companies and their investors, is pleased to announce that their agribusiness investment banking group has advised on three sellside transactions in the past nine months. The transactions included business models in the areas of cover crops, gene editing, biologicals, bio stimulants, and alternative fertilizers, and demonstrate the group's expertise in designing and executing M&A processes to achieve the best outcomes for its clients in a wide array of agriculture related sectors. ROTH MKM's Agribusiness Investment Banking Group served as the sellside advisor on the following transactions:

      4/11/23 9:00:00 AM ET
      $BG
      $BIOX
      $CTVA
      $CVX
      Packaged Foods
      Consumer Staples
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions Completes Merger With Marrone Bio, Creating a Global Leader in Sustainable Agricultural Solutions

      Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. (NASDAQ:MBII) ("MBI"). "The completion of this transaction represents an important milestone in our journey, cementing our leadership in the development and commercialization of sustainable agricultural solutions," said Bioceres Chief Executive Officer, Federico Trucco. "MBI brings 15 years of experience in the development of biological solutions, and we are excited to a

      7/12/22 4:43:00 PM ET
      $BIOX
      $MBII
      Agricultural Chemicals
      Industrials
      Major Chemicals
      Basic Industries
    • Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp.

      RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI's stockholders approved the adoption of the Merger Agreement and approved on a non-binding advisory basis certain executive compensation that may be paid or become payable in connection with the merger contemplated by t

      7/11/22 8:30:00 AM ET
      $BIOX
      $MBII
      Agricultural Chemicals
      Industrials
      Major Chemicals
      Basic Industries

    $MBII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Marrone Bio Innovations with a new price target

      Roth Capital initiated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.00

      9/22/21 11:59:03 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • Aegis Capital reiterated coverage on Marrone Bio Innovations with a new price target

      Aegis Capital reiterated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.50 from $3.50 previously

      8/19/21 9:34:56 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • Canaccord Genuity resumed coverage on Marrone Bio Innovations with a new price target

      Canaccord Genuity resumed coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $3.50

      3/5/21 7:31:59 AM ET
      $MBII
      Major Chemicals
      Basic Industries

    $MBII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Marrone Bio Innovations Inc. (Amendment)

      SC 13D/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)

      7/15/22 9:12:06 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form SC 13G/A filed by Marrone Bio Innovations Inc. (Amendment)

      SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)

      3/29/22 11:21:42 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form SC 13G/A filed by Marrone Bio Innovations Inc. (Amendment)

      SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)

      2/14/22 12:25:35 PM ET
      $MBII
      Major Chemicals
      Basic Industries